Anavex Life Sciences (AVXL) Retained Earnings (2011 - 2025)

Anavex Life Sciences (AVXL) has 15 years of Retained Earnings data on file, last reported at -$388.1 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 11.47% year-over-year to -$388.1 million; the trailing twelve-month figure through Dec 2025 stood at -$388.1 million (down 11.47% YoY), and the FY2025 full-year result was -$382.4 million, down 13.8% from the prior year.
• Retained Earnings declined to -$388.1 million in Q4 2025, from -$382.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$175.7 million in Q1 2021 to a low of -$388.1 million in Q4 2025.
• A 5-year average of -$284.7 million and a median of -$288.0 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings slipped 24.6% in 2022 and slipped 11.47% in 2025, its largest moves.
• Tracing AVXL's Retained Earnings over 5 years: stood at -$208.5 million in 2021, then retreated by 24.02% to -$258.5 million in 2022, then dropped by 16.69% to -$301.7 million in 2023, then declined by 15.41% to -$348.2 million in 2024, then slipped by 11.47% to -$388.1 million in 2025.
• Business Quant data shows AVXL's Retained Earnings at -$388.1 million in Q4 2025, -$382.4 million in Q3 2025, and -$372.6 million in Q2 2025.